Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials - Test2 - elhamkhani - TriplyDB

Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials

Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials

http://www.wikidata.org/entity/Q26773290

about

Don't stress about CRF: assessing the translational failures of CRF1antagonists.Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers.Pathophysiology and Management of Alcoholic Liver Disease: Update 2016.Review article: pharmacotherapy for alcohol dependence - the why, the what and the wherefore.[Trends in pharmaceutical care for men].Evaluation in alcohol use disorders - insights from the nalmefene experience Opioid substitution therapy or hidden opioids are a minefield for nalmefene: an atypical case series of 11 patients in Lorraine.Reduced Drinking in Alcohol Dependence Treatment, What Is the Evidence?Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate.Reply to Naudet and Colleagues. Cost-Effectiveness in Health Technology Assessment-A Case in Alcohol Dependence.A Point-by-Point Response to Braillon.Practical outpatient pharmacotherapy for alcohol use disorder.Recommendations of French Alcohol Society and European Federation of Addiction Societies.Alkohol

P2860

Q30399543-0943CED9-A970-4EA3-886B-DC1CFB06CB4C Q37384923-13F833EA-CF3C-4353-8C3A-032400EE7AA9 Q37696026-BC97E8C8-C92C-4556-B9FD-880AC2FE7D73 Q39144955-C46201D0-C4E5-4F63-977B-68C190FA1AE3 Q40678644-6A1E4271-9B45-44EE-97AF-C2BDDA641DCB Q42348636-9CD294FF-86A9-428D-AFDE-BDA88CC314D0 Q44344147-EB87081A-948C-4877-9EC8-8D09439FBD62 Q47616924-B3EC7CA2-23E7-479F-B418-DB11695E490E Q47936236-A0A76C6C-42A4-4FF2-A414-E57934D718F0 Q48008884-DBDAD8D6-CF49-49E4-A38B-0324E0621C1D Q48024508-887457D3-F194-454F-B5E9-A3C857950404 Q50317988-0569BE33-202D-439E-8758-A1B3EBEABF6C Q52309414-D352DD34-1862-48F0-8F55-C6A8226CCF5B Q56700847-1A910058-F0D0-43C8-AEBD-A99155708F5F

P2860

Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials

http://www.wikidata.org/entity/Q26773290

description

2015 nî lūn-bûn

@nan

2015 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Risks and Benefits of Nalmefen ...... d Randomized Controlled Trials

@ast

Risks and Benefits of Nalmefen ...... d Randomized Controlled Trials

@en

Risks and Benefits of Nalmefen ...... d Randomized Controlled Trials

@nl

type

label

Risks and Benefits of Nalmefen ...... d Randomized Controlled Trials

@ast

Risks and Benefits of Nalmefen ...... d Randomized Controlled Trials

@en

Risks and Benefits of Nalmefen ...... d Randomized Controlled Trials

@nl

prefLabel

Risks and Benefits of Nalmefen ...... d Randomized Controlled Trials

@ast

Risks and Benefits of Nalmefen ...... d Randomized Controlled Trials

@en

Risks and Benefits of Nalmefen ...... d Randomized Controlled Trials

@nl

P1433

Q26773290-B9C3EADE-458C-43E7-AC2D-79F0010602C3

P1476

Q26773290-93399166-2DE1-4C0D-BA59-1CB7ACB96AC2

P2093

Q26773290-3BAB615F-FFEE-4063-9558-6A7212613FC7

Q26773290-6A982890-A397-4FB0-9042-9A94D0DE6A8A

Q26773290-A5BFB063-4863-4DDF-A9A6-F690448F8F04

Q26773290-B76BA618-2736-43F8-B82A-4E80B45FF358

Q26773290-B86ECBFE-A57A-46D9-97D6-75BCC400ECD2

P275

Q26773290-3A61E532-6A68-496B-9FB8-CB4224945048

P2860

Q26773290-1C245CA3-F0AE-40DC-BB6F-902C901138AA

Q26773290-28B719D7-D9B0-4466-B4F7-D3D9F48637BF

Q26773290-2CF91A27-4A1A-4F45-8804-509099F0EC90

Q26773290-2D51CB45-A31B-48A4-B92B-3F2E49CCB24D

Q26773290-31144CDF-3898-4D34-B41F-F5A4BE354E52

Q26773290-357E2495-396D-48EF-B60F-994DEE02E6D8

Q26773290-3854B670-2E70-4D2D-8072-F8F122E0C3B6

Q26773290-38E0BF3B-9144-42E8-8CC3-605A14E055DD

Q26773290-395A1B88-E4DA-4B78-A1DA-04F44C135FA6

Q26773290-3A55FD4B-16C2-4C5A-870E-FD3477FDE542

P304

Q26773290-598A84D1-D822-4951-B91E-F6FE43AD15E8

P31

Q26773290-CE353F09-FADA-44B7-AED8-06C3A43AF303

Q26773290-EBA8FB65-1092-4D0B-97AB-62494D5DDAB2

Q26773290-F46190F1-B37D-453A-B12B-19EFF5A6D19A

P3181

Q26773290-D4594C91-FBBF-4D43-A828-E115407DA597

P356

Q26773290-01CCB940-F11A-49F9-A602-06C0B8DDCA21

P407

Q26773290-16A700E6-40F0-49AC-B089-4BF5889B369C

P433

Q26773290-D1C3B5EB-4D21-4A77-88FF-F2D48EEBCFB2

P478

Q26773290-6230A1CF-8FE0-457D-97E4-30FC5D93AE54

P50

Q26773290-66619CBD-E2BA-4576-8033-80C8E359CC41

P5008

Q26773290-B1F0EA4D-243E-44EF-B6D9-03E972F0D601

P577

Q26773290-354E6128-580B-4378-82C7-E0C841DD4906

Q26773290-6EB7D29A-C827-4A02-A2DE-851E63B0E11F

P5875

Q26773290-14D36EFC-CAE6-4A20-BE32-BDB9157AC0CF

P698

Q26773290-D923F9A1-2B38-4E69-8460-CEF29402D2D6

P921

Q26773290-07DFD146-C7BA-4BF0-AB4D-4C382E30C63E

Q26773290-5BCD1B97-5EA5-43E9-87A9-9B755671676B

Q26773290-716CED37-EBA4-4A46-981A-885FBFE63597

Q26773290-cf8b4a2f-4906-4e63-9fe3-126879e2984c

P932

Q26773290-B5B20CE4-7557-4050-A005-3641B8511E4D

P3181

P356

JOURNAL.PMED.1001924

P1433

P1476

Risks and Benefits of Nalmefen ...... d Randomized Controlled Trials

@en

P2093

Bruno Laviolle

http://www.w3.org/2001/XMLSchema#string

Clément Palpacuer

http://www.w3.org/2001/XMLSchema#string

Eric Bellissant

http://www.w3.org/2001/XMLSchema#string

Jean Michel Reymann

http://www.w3.org/2001/XMLSchema#string

Rémy Boussageon

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

Managed alcohol as a harm reduction intervention for alcohol addiction in populations at high risk for substance abuse

Nalmefene: a new approach to the treatment of alcohol dependence

Debate: Subgroup analyses in clinical trials: fun to look at - but don't believe them!

Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders

Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials

Harm reduction approaches to alcohol use: health promotion, prevention, and treatment.

Methods to analyze treatment effects in the presence of missing data for a continuous heavy drinking outcome measure when participants drop out from treatment in alcohol clinical trials.

A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence.

Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study.

P304

e1001924

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4030819

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PMED.1001924

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

P5008

P577

2015-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2015-12-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

287971671

http://www.w3.org/2001/XMLSchema#string

P698

26694529

http://www.w3.org/2001/XMLSchema#string

P921

heterocyclic compound

polycyclic compound

P932

4687857

http://www.w3.org/2001/XMLSchema#string